According to the Wall Street Journal, the U.S. Food and Drug Administration is considering new standards for drugs used in the treatment of the disabling condition of diabetes.
According to the WSJ, the FDA is considering benchmarks which would establish a requirement for pharmaceutical companies to provide proof that the drugs will reduce the risk of heart attack or increase diabetics’ life spans. Current benchmarks such as blood sugar reduction are easier to measure.
According to the newspapers, there were two large scientific studies which discovered no evidence of aggressive reduction in blood sugar levels increasing the life expectancy or cardiovascular health of diabetics.
The FDA is also considering establishing a requirement for pharmaceutical companies to prove that diabetes drugs which are currently on the market do not increase the risk of heart disease.